Neurocrine Biosciences, Inc. - Common Stock (NBIX) stock analysis
NBIX · Neurocrine Biosciences, Inc. - Common Stock
Latest recorded price: USD 165.31
Model-estimated fair value: USD 178.69. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic
At $165.31, NBIX trades 7.5% below the model's base-case value of $178.69. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $136.00 in the conservative case and $230.09 in the optimistic case, with a valuation confidence score of 75/100. Fiscal 2025 figures: revenue growth 24.3%, free cash flow margin 26.2%, ROIC 19.4%. The model does not flag any risk signals for this company.
Similar companies in Healthcare
- Phibro Animal Health Corporation (PAHC)
- Prestige Consumer Healthcare Inc. (PBH)
- Pacira BioSciences, Inc. (PCRX)
- Perrigo Company plc (PRGO)
- Supernus, Inc. - Common Stock (SUPN)
- Teva Pharmaceutical Industries Limited Ordinary Shares (TEVA)
- Trulieve Cannabis Corp. (TRLV)
- United Therapeutics Corporation - Common Stock (UTHR)